86 results about "Catabolism" patented technology

A method for enhancing hydrogen uptake by cells of an acetogenic bacterium in a culture is provided. The method comprises incubating the cells in a liquid medium supplemented with an external gas mixture, wherein the external gas mixture comprises H2 and CO2; overexpressing an uptake hydrogenase and an associated electron transfer protein in the cells; increasing uptake of the H2 by the cells; and enhancing uptake of the CO2 by the cells. The culture may be a coculture with additional cells of a non-acetogenic bacterium, which produces natively H2 from catabolism of an organic molecule.

The invention discloses weight-reducing and blood-sugar-reducing meal replacement powder for increasing satiety and a preparation method thereof, and belongs to the technical field of meal replacement powder. Comprising resistant starch, bio-enzyme modified whey protein concentrate, bio-enzyme modified soybean protein isolate, bio-enzyme modified white kidney bean hydrolyzed protein, oat fiber powder, nano emulsion milk powder, mogroside, chitosan, inulin, konjac powder, pumpkin seed powder, a cactus extract, a griffonia simplicifolia seed extract and a Chinese waxgourd peel extract. Through the synergistic effect of multiple components and multiple processes, the obvious effects of satiety, weight loss and blood sugar reduction are achieved. 5-hydroxytryptophan in the griffonia seed extract can regulate satiety center and delay hunger sensation; dietary fibers such as the resistant starch and the inulin absorb water and swell in intestinal tracts to form high-viscosity gel, so that the satiety is further enhanced, and the eating frequency and the eating amount are reduced. A low-calorie and high-protein formula is combined with components such as tartronic acid in the Chinese waxgourd peel extract and the cactus extract, so that fat catabolism is accelerated, and fat synthesis is inhibited.

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.

Particulated and reconstituted tissues comprising small, densely packed tissue microparticles encapsulated in a tissue specific promoting gel packed at a percolation threshold that can be transplanted into damaged tissue thereby facilitating regeneration following trauma to the tissue. The engineered microparticle construct for tissue replacement and repair, as taught herein, provides numerous benefits including (1) encouraging a regenerative response in damaged tissue regions, (2) mimicking the structural support of native tissue, (3) establishing an environment that promotes attachment, migration, and differentiation of infiltrating stem cells, and (4) providing a source of growth factors and other anti-catabolic growth factors and cytokines. Tissue specific microparticles packed together at, or past, their percolation threshold will provide the necessary mechanical environment and to best recapitulate and integrate with native tissue. The packing of microparticles, derived from the ECM of native tissue to a concentration past the percolation point will yield both the necessary biochemical and biomechanical properties necessary for reconstituting a specific tissue.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

The present invention discloses the preparation of plantain polysaccharide and its application in the preparation of drugs for preventing and treating fatty liver and hemorrhagic syndrome in laying hens, belonging to the field of biomedicine technology. The present invention also provides the application of plantain polysaccharide in the preparation of feed additives for regulating and / or treating fatty liver in laying hens. The present invention comprehensively explores the preventive and therapeutic effects of different doses of plantain polysaccharide on fatty liver in laying hens induced by high-energy and low-protein diets through in vitro and in vivo experimental modeling and detection of relevant indicators, and reduces liver fat deposition by regulating liver fat synthesis and oxidative catabolism and ferroptosis-related signaling pathways, thereby effectively preventing and treating fatty liver and hemorrhagic syndrome in laying hens induced by high-energy and low-protein diets. The present invention also studies the preventive and therapeutic effects of plantain polysaccharide on egg production and fatty liver in laying hens, and concludes that plantain polysaccharide can increase egg production in laying hens and improve production performance.

The present disclosure relates to the use of a switch for the production of heterologous non-catabolic compounds in microbial host cells. In one aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured under aerobic conditions followed by microaerobic conditions, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions. In another aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured in the presence of maltose followed by the reduction or absence of maltose, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions.

The present disclosure relates to a kit. The kit of the present disclosure comprises: a kit body comprising a needle tube and a needle, the first end of the needle being mounted to the needle tube; and a catabolic filling thread comprising a first segment and a second segment connected to each other, at least a part of the first segment being located inside the needle, and at least a part of the second segment being located outside the needle, wherein the catabolic filling thread is a thread made of poly-L-lactic acid. The kit of the present disclosure comprises a catabolic filling thread which can be composed of poly-L-lactic acid, is absorbable, has no residue, and is metabolized into lactic acid in the human body. Such a configuration makes the catabolic filling thread itself not only play a role in filling and tightening when filling surgery is performed using the catabolic filling thread of the present disclosure, but also the lactic acid after its metabolism can still stimulate fibroblasts in the skin and subcutaneous tissue to reconstruct the collagen framework in the human body by using fibroblasts.

The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of miR-206-3p in regulation and control of skeletal muscle atrophy, and the change condition of the miR-206-3p level is measured by constructing an in-vitro cancer cachexia myotubular atrophy model; it is verified that in-vitro addition of miR-206-3p mimics relieves in-vitro myotube atrophy induced by a cancer conditioned culture medium, inhibits expression of a myotube marker gene and inhibits proteolysis and metabolism pathways and cell apoptosis of myotubes, so that myotube atrophy induced by cancer cachexia is inhibited. The invention opens up a new thought for the research of cachexia pathogenesis, and also provides a potential new target for the research and development of cachexia treatment and / or cachexia prevention drugs.

The invention provides a fat-reducing nutritional composition containing a kelp extract and a preparation method of the fat-reducing nutritional composition, belongs to the technical field of foods, and relates to fermentation engineering and marine food manufacturing. The fat-reducing nutritional composition comprises the following components: a kelp extract, opuntia ficus-indica powder, an enhancer, a flavoring agent and a nutritional agent, wherein the enhancer is prepared from calcium beta-hydroxy-beta-methyl butyrate, catechin and betaine. The fat-reducing nutritional composition disclosed by the invention is scientific in compatibility of the components, can effectively regulate catabolism of fat, improve fat consumption, reduce fat accumulation, timely supplement nutrition, prevent muscle loss, synchronously improve the metabolic level and immunity of a body, and achieve the effects of health and fat reduction.

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and / or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.

A method of breaking down at least one component of a substrate can include providing a catabolic nanocompartment that includes a liquid coacervate phase, at least one catalyst within the coacervate phase, and an aqueous phase surrounding the coacervate phase. The method can include contacting the catabolic nanocompartment with the substrate including the at least one component such that the catalyst degrades the at least one component and forms degradation products of the at least one component.

The invention discloses application of chlorella in preparation of a medicine for treating osteoarthritis, in-vivo experiments and in-vitro experiments prove that chlorella can maintain a chondrocyte metabolism steady state, inhibit expression of chondrocyte extracellular matrix catabolism-related genes and proteins, and inhibit osteoarthritis. The expression of genes and proteins related to chondrocyte extracellular matrix anabolism is promoted, and by injecting a chlorella solution into a knee joint cavity, the effects of relieving and improving OA pain are achieved; furthermore, polydopamine is used for modifying the chlorella to obtain the polydopamine-coated chlorella Ch (at) P with a photothermal effect, and the Ch (at) P not only maintains the biological activity of the chlorella, but also has the effect of delaying cartilage degeneration and OA process due to the photothermal effect under near infrared (NIR) irradiation.

The invention provides recombinant cinnamon streptomyces and application thereof in monensin production, and belongs to the technical field of microbial fermentation and antibiotic preparation. According to the recombinant cinnamon streptomyces provided by the invention, a ccr gene with a nucleotide sequence shown as SEQ ID NO.2 in the cinnamon streptomyces is knocked out, and an xylA gene with a nucleotide sequence shown as SEQ ID NO.1 is overexpressed. According to the recombinant cinnamon streptomyces provided by the invention, through overexpression of the xylA gene, the metabolic capability of the cinnamon streptomyces to xylose is enhanced; the ccr gene is knocked out, so that the carbon catabolism inhibition phenomenon is weakened, and the xylose utilization rate is increased when the recombinant strain takes xylose as a carbon source. The recombinant streptomyces cinnamomi provided by the invention can improve the titer of monensin, reduce the production cost, shorten the fermentation period and improve the production efficiency.

The present disclosure provides an engineered nucleic acid sequence comprising a gene cassette, the gene cassette comprising one or more regulator genes, the regulator genes including an iadR gene, and at least three catabolic pathway genes downstream from the one or more regulator genes, the at least three catabolic pathway genes including an iadC gene, an iadD gene, and an iadE gene, wherein the engineered nucleic acid sequence is free of an iadA gene and iadB gene. The disclosure also provides bacteria cells comprising the engineered nucleic acid sequence, wherein the bacteria cell is capable of degrading indole-3-acetic acid. Methods for degrading auxin, controlling auxin, and promoting plant growth and root development are provided, comprising providing the bacteria cell and allowing the bacteria cell to interact with roots of a plant.

This invention discloses a kitten food without palatability enhancers and its preparation method, relating to the field of pet food technology. It comprises the following components: polypeptide chicken meal, soy protein peptides, gluten hydrolysate, lactoferrin, astragalus extract, yam powder, rosemary oil, resveratrol, tributyrate, and rice. By adding substances containing small peptides and plant extracts to the kitten food, this invention provides the body with a large amount of high-quality animal protein without adding any chemically synthesized palatability enhancers, preservatives, or other chemical additives. This effectively promotes the body's decomposition and metabolism of nutrients, promotes the growth of kittens, and also enhances the body's antioxidant capacity and reduces the occurrence of diarrhea.

The invention provides China-hemp peptide nutritional fat-reducing yoghourt and a preparation method thereof. Comprising the following raw materials in parts by weight: 85-92 parts of a fermented milk substrate, 1.2-1.8 parts of China-hemp protein, 0.02-0.05 part of a probiotic starter, 0.8-1.2 parts of China-hemp seeds and 4-6 parts of China-hemp seed oil microcapsule powder. The China-hemp peptide is combined with the yoghourt, so that the fat-reducing effect is remarkably improved while the taste of the product is ensured. Small-molecule active peptide obtained after extraction and hydrolysis of China-hemp protein can effectively inhibit lipase activity and promote catabolism of fat, and the function of regulating lipid metabolism is further enhanced through the synergistic effect of the small-molecule active peptide and probiotic strains. Through compounding use of the hemp seeds and the hemp protein, the stability problem of hemp peptide in an acid environment is solved, and the common defect of thin texture of traditional fat-reducing yoghurt is avoided. The prepared China-hemp peptide nutritional fat-reducing yoghurt is fine and full in texture, the biological activity of China-hemp peptide is fully reserved, the flavor is coordinated and natural, and the product has a definite fat-reducing function and also keeps the eating experience of traditional yoghurt.

The invention discloses a fusarium graminearum pathogenicity inhibition method based on carbon metabolism regulation and application of the fusarium graminearum pathogenicity inhibition method, and belongs to the field of agricultural disease control. The invention finds that the strain Pseudomonas sp.CXZ8 can influence the infection adaptability of fusarium graminearum through a targeted carbon catabolism repression pathway, that is, the strain Pseudomonas sp.CXZ8 can inhibit the expression of a fucosidase gene Fco1, interfere the nutrition utilization of pathogenic bacteria and prevent the pathogenic bacteria from infecting crops. Field and greenhouse inoculation tests prove that the disease index of the wheat scab can be remarkably reduced by spraying a fungicide prepared from the strain. Compared with traditional biological prevention and control, the invention provides a biological prevention and control strategy with carbon metabolism regulation as a target spot. The strategy provides possibility for accurately intervening the environmental adaptability of pathogenic bacteria and realizing prevention and control from the source, and also provides theoretical basis and technical support for green prevention and control work of wheat scab.

The invention provides application of pentenedioic acid (GC) in enhancing the anti-tumor effect of T cells through metabolic reprogramming, and belongs to the technical field of biological medicine. It is found that in the tumor development process, GC is supplemented in an exogenous mode, tumor growth can be rapidly inhibited, and the anti-tumor effect depends on a TME regulation and control mechanism. Through GC treatment, the TME immune landscape can be significantly remodeled; gC treatment not only can enhance the effector function of the CD8 + T cells, but also can delay the depletion process of the CD8 + T cells; and the infiltration CD8 + T cells in the tumor of the GC treatment group are obviously increased. Particularly, after the CD8-resistant antibody is used for removing mouse CD8 + T cells, the anti-tumor effect of GC completely disappears, and it is confirmed that the tumor inhibition effect depends on the CD8 + T cells. Therefore, the invention proves that the lysine catabolic metabolite GC, as an immunostimulatory metabolite, can shape the immune activated TME by reactivating the functions of tumor infiltrating CD8 + T cells.

Increased control and efficiency over the wastewater purification can be achieved by allowing to selectively prioritize catabolic over anabolic processes via prioritization of the digestive function of microorganism in the activated sludge. The gas-dispersion return sludge is created using pure oxygen or oxygen containing trace amounts of ozone, which is blended with return sludge to create a mixture of gas and liquid, which is passed through an atomizer or a pump to instantly render the reactive gas to an ultra-fine bubble state. At least a portion of the ultra-fine bubbles dissolve within the sludge, raising oxygen to a critical level within a short time, activating the dormant microorganisms. The microorganisms accumulate enough cATP upon initial encounter with the pollutants to prioritize their digestive function, and when exposed to pollutants present in wastewater, digest the pollutants using biochemical pathways different from the ones used in nature.

The present invention provides for a library of binary vectors comprising a first library of first binary vectors, and a second library of second binary vectors, which in combination comprise genes of interests of a biosynthetic pathway or a catabolic pathway. The present invention provides for a method for introducing the genes of interest encoding for the enzymes of a biosynthetic pathway or a catabolic pathway into a target host cell comprising: (a) providing a library of host cells, (b) contacting the library of host cells to a target host cell resulting in introducing the genes of interest into the target host cell, and (c) identifying one or more the target host cell that are capable of synthesizing or catabolizing the compound of interest.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The present disclosure relates to a pectin-containing wastewater treatment method and a treatment device, the method comprising: inputting first pectin wastewater into a biological conversion tank, and performing biological conversion treatment on pectin in the first pectin wastewater based on a pectin-cellulose degradation mixed bacteria to obtain second pectin wastewater containing small molecular structure pectin; wherein the pectin-cellulose degradation mixed bacteria is a mixed bacterial population capable of simultaneously degrading pectin and cellulose, and the biological conversion treatment process is used to change the pectin structure without affecting the chemical oxygen demand corresponding to the first pectin wastewater; inputting the second pectin wastewater into a primary or multi-stage anaerobic reactor for anaerobic decomposition treatment to obtain wastewater with reduced organic matter concentration after pectin decomposition and biogas; and the biogas is used for input into a power supply end or an energy storage end for recycling. In the wastewater treatment process, in-situ treatment and relatively sufficient degradation of pectin are achieved, and the treatment load and treatment efficiency are improved.

The invention discloses a feed additive for reducing the cholesterol content of pork as well as a preparation method and application thereof, and belongs to the technical field of feeds. The additive is prepared from the following components in percentage by mass: 10 to 20 percent of phytosterol, 8 to 15 percent of tea polyphenol, 5 to 10 percent of soybean isoflavone, 5 to 10 percent of bacillus, 5 to 8 percent of clostridium butyricum, 3 to 5 percent of lactobacillus fermentum, 2 to 5 percent of selenium yeast, 8 to 12 percent of xylooligosaccharide, 5 to 8 percent of chitosan oligosaccharide and the balance of corn starch. The preparation method comprises the steps of superfine grinding of the plant extract, microencapsulation activation of the probiotics, homogenization treatment of the functional oligosaccharide, low-temperature mixing and the like. When in use, the feed additive is added into basic ration according to the proportion of 0.5-1.5%. Through a ternary compound system of the plant extract, the probiotics and the functional oligosaccharide, endogenous synthesis is inhibited through multi-target synergism, catabolism is promoted, exogenous absorption is reduced, the cholesterol content of pork can be remarkably reduced by 23% or above, meanwhile, the growth performance and meat quality of pigs are improved, economic benefits are remarkable, and the feed additive is suitable for producing high-added-value healthy pork.

The invention belongs to the field of biological medicine, and particularly discloses a pharmaceutical application of an AR agonist based on bioinformatics targeted screening in sepsis sarcopenia, and the core is that the AR agonist Ostarine is adopted to specifically activate muscle AR and improve SIS through subcutaneous injection administration in the acute stage (within 5 days) of sepsis. The mechanism comprises the following steps: (1) recovering skeletal muscle protein synthesis (up-regulating p-AKT / p-mTOR) and decomposing metabolic balance (down-regulating Atrogin-1 / MuRF1); (2) promoting the expression of a polyamine biosynthetic gene (AMD / ODC1 / SMOX); and (3) adjusting the ratio of fast and slow muscle fibers (promoting MyoD and inhibiting MHC I and TnI-flow). Experiments show that Ostarine (5mg / kg) can significantly improve the survival rate, muscle weight and grip strength of sepsis mice within 5 days and reverse amyotrophy. In addition, the invention provides an SIS drug screening method based on the RNA binding protein Hnrnpa1 (regulating AR pre-mRNA). The method is easy and convenient to operate and high in targeting performance, and a new strategy is provided for treatment of sepsis sarcopenia.

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.

The invention discloses application of euglena and a product thereof to improvement of hyperuricemia. The euglena and the product thereof are used for improving the hyperuricemia. The euglena and the product thereof improve hyperuricemia by reducing uric acid and protecting the kidney from uric acid damage. The uric acid reducing effect of the euglena and the euglena product and the uric acid reducing effect of the medicine febuxostat have a superposed effect According to the euglena and the euglena product, intestinal flora is regulated by promoting probiotic flora in the intestinal tract and inhibiting growth of harmful flora in the intestinal tract, catabolism of purine and uric acid in the intestinal tract is promoted, and uric acid metabolism is regulated. The euglena and products thereof include euglena and euglena polysaccharides. The invention provides a new method for treating people with hyperuricemia. The euglena and the euglena polysaccharide improve hyperuricemia by reducing uric acid and protecting kidneys from being damaged by uric acid, regulate intestinal flora by promoting probiotic flora in intestinal tracts and inhibiting growth of harmful flora in the intestinal tracts, promote catabolism of purine and uric acid in the intestinal tracts and regulate uric acid metabolism.

The invention provides yeast engineering bacteria for producing L-tryptophan by utilizing methanol carbon source fermentation and application, and belongs to the technical field of biology. According to the engineered yeast, a methanol substrate is coupled with a methanol inducible promoter induction system, so that the gene expression intensity is dynamically matched with the methanol consumption rate, and the problem of regulation lag caused by separation of an inducer and a substrate in a traditional carbon source is solved; in addition, a gene recombination technology is adopted to enhance expression of key genes in the synthesis route of the L-tryptophan, and the biosynthesis efficiency of the L-tryptophan is remarkably improved by increasing the dosage of target genes, enhancing supply of precursor substances and knocking out genes related to catabolism of the tryptophan in chassis cells at the same time. The constructed yeast engineering bacterium has the characteristics of clear metabolic background and strong heterologous expression ability, can be used for synthesizing L-tryptophan from the beginning completely by taking methanol as a carbon source, effectively gets rid of the dependence of a traditional process on grain resources, reduces the production cost, and provides a brand new technical path for industrial production of L-tryptophan.